Female HRT replaces the estrogen and progesterone lost at menopause. The strongest, most consistent gains are relief of hot flashes and night sweats, protection against bone loss and fractures, and reversal of vaginal and urinary changes. Starting early may also support heart and brain health. Real risks include blood clots, stroke, and breast cancer. (Full Review)

Protocol

Estrogen

Transdermal estradiol, low dose

Patch, gel, or spray (e.g., 25–50 µg/day); titrate to symptom relief

Progestogen

Micronized progesterone if uterus intact

100–200 mg at bedtime; prevents endometrial overgrowth from unopposed estrogen

Timing

Start before age 60 or within 10 years of menopause

Aligns with the favorable side of the timing hypothesis for heart and brain

Time to effect

Hot flashes & night sweats

2–4 weeks

Fuller benefit by 8–12 weeks

Vaginal symptoms

Several weeks

With consistent use

Bone density

Months to years

Assessed with periodic scans

Benefits

High: Relief of vasomotor symptoms; prevention of bone loss and fractures; treatment of genitourinary syndrome of menopause

Medium: Reduced all-cause mortality with early initiation; improved cardiovascular risk markers in early menopause; reduced type 2 diabetes risk

Low: Lower risk of colorectal cancer; reduced dementia risk with midlife estrogen initiation

Speculative: Skin collagen and connective tissue maintenance; preservation of lean muscle mass

Contraindications

Current or past breast cancer or other estrogen-sensitive cancer

Unexplained vaginal bleeding

Active or recent venous thromboembolism

Recent stroke or heart attack (<12 months)

Active liver disease

Known inherited high-risk clotting disorders

Concurrent hormonal contraceptives

Key Interactions

Enzyme-inducing drugs (carbamazepine, phenytoin, rifampin)

CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin)

Thyroid hormone (levothyroxine)

NSAIDs (ibuprofen)

St. John's Wort

Grapefruit-derived supplements

Phytoestrogen supplements (soy isoflavones, red clover, Siberian rhubarb)

Tamoxifen

Risk & Side Effects

High: Venous thromboembolism (blood clots); stroke; breast cancer with combined therapy

Medium: Gallbladder disease; endometrial cancer with unopposed estrogen

Low: Dementia with late-life combined therapy; coronary events with late initiation

Speculative: Ovarian cancer; increased mammographic density and screening complexity

Monitoring

Marker	Target	Why
Blood pressure	<120/80 mmHg	Detects hypertension that raises stroke risk on HRT
Estradiol (serum)	~50–100 pg/mL on therapy	Confirms adequate absorption, especially transdermal/compounded
Lipid panel (LDL, HDL, triglycerides)	LDL <100 mg/dL; triglycerides <100 mg/dL	High triglycerides worsen oral-estrogen clot/gallbladder risk
Fasting glucose / HbA1c	Glucose <90 mg/dL; HbA1c <5.4%	Tracks the metabolic/diabetes effect of estrogen
Bone mineral density (DEXA T-score)	T-score above -1.0	Confirms the skeletal benefit and guides duration
Vitamin D (25-OH)	40–60 ng/mL	Supports the bone benefit of estrogen

Cadence: 6–12 weeks after initiation or dose change, then at least annually; bone density every 1–2 years

Qualitative Assessment

Hot flash and night-sweat frequency
Sleep quality
Energy and mood
Cognitive clarity
Vaginal and urinary comfort

Female HRT for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment